The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Understanding resistance to antibody-drug conjugates in lung cancer treatment
Samreen Ahmed, FRCP, MD, MBBS, MSc, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses her presentation on antibody-drug conjugate (ADC) resistance at BTOG 2025. Drawing from her experience in breast cancer treatment, where ADCs have been widely used, she explores how insights from HER2-targeted therapies can inform lung cancer management. Her talk highlighted the evolving understanding of resistance mechanisms and their implications for future treatment strategies. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
